Bottom line
FHLC vs LOGSX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.
But FHLC is far broader, holding 337 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
FHLC is cheaper at 0.084% vs 1.04% — a difference of $96 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +7.2% for FHLC (reporting dates differ).
Updated Nov 19, 2026
FHLC vs LOGSX side by side
| FHLC | LOGSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 1.04% |
| Annual cost per $10k | $8.4 | $104 |
| 10-yr cost on $10k (prospectus) | $108 | $1,271 |
| Max front load | None | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +2.6% | +19.6% |
| 5-yr return (annualized) | +7.2% | +8.1% |
| 10-yr return (annualized) | +8.8% | +7.3% |
| Best quarter | +16.4% | +13.4% |
| Worst quarter | −13.1% | −13.1% |
| Net assets (fund) | $3.3B | $56.1M |
| Number of holdings | 337 | 28 |
| Portfolio turnover | 3% | 24% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | LOGSX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +0.2% | +2.4% |
| 2023 | +2.5% | +1.2% | +1.3% |
| 2022 | −5.5% | +3.7% | −9.2% |
| 2021 | +20.4% | +17.5% | +2.9% |
| 2020 | +18.1% | +6.0% | +12.2% |
| 2019 | +21.9% | +19.0% | +3.0% |
| 2018 | +5.5% | −4.0% | +9.5% |
| 2017 | +23.3% | +13.4% | +9.9% |
| 2016 | −3.3% | −0.4% | −3.0% |
Source: Fund prospectus bar charts
Holdings overlap
13 of FHLC's top 25 holdings also appear in LOGSX's top 25.
| Holding | FHLC | LOGSX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 1.99% |
| Johnson & Johnson | 8.93% | 3.77% |
| Merck & Co Inc | 4.66% | 3.16% |
| Amgen Inc | 3.00% | 4.86% |
| Gilead Sciences Inc | 2.34% | 3.50% |
| Bristol-Myers Squibb Co | 1.93% | 4.02% |
| Intuitive Surgical Inc | 1.82% | 2.99% |
| Vertex Pharmaceuticals Inc | 1.76% | 3.26% |
| McKesson Corp | 1.52% | 4.53% |
| Regeneron Pharmaceuticals Inc | 1.15% | 4.43% |
| Cigna Group/The | 1.06% | 3.46% |
| Cencora Inc | 0.83% | 4.46% |
| Cardinal Health Inc | 0.78% | 5.86% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between FHLC and LOGSX?
Which is cheaper, FHLC or LOGSX?
Should I own both FHLC and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.